Home Archive Vol.42, No.4, 2016 Therapeutical Attitude and Analysis of Results in Brain Metastases

Therapeutical Attitude and Analysis of Results in Brain Metastases

Anda Crisan(1), F. Badulescu(1), M. Popescu(2), I. Andrei(3)

(1)Department of Medical Oncology,University of Medicine and Pharmacy Craiova, Clinical Emergency County Hospital, Craiova, (2)Department of Radiology,University of Medicine and Pharmacy Craiova, Clinical Emergency County Hospital, Craiova, (3)VI year student, University of Medicine and Pharmacy, Craiova

    Abstract: Objectives - The aim of this study is to assess therapeutic outcomes in patients presenting with brain metastases as the first manifestation of malignancies either as a final stage in the evolution of malignancies. Materials and methods - We’ve performed a complex retrospective study on a total of 81 patients with brain metastases treated in Medical Oncology Clinic of the Emergency County Hospital Craiova between 1 January 2005-31 December 2010. Results - The average age of women (55 years) was statistically significantly low compared to men (64 years) (p = 0.000). The most affected age group was 51-60 years in women with maximum frequency of breast cancer and 61-70 years for men, with predominance of lung cancer. Most cases were presented with multiple metastases (90.12%) and the average latency-free interval from primary tumor detection to onset of symptoms was 29.8 months. Clinical manifestations, in most cases, occurred in less than 6 months after diagnosis of the primary tumor being a consequence of the evolution of disease at distance (36 patients / 62 patients in oncological evidence 58.06%) and 12 months after diagnosis survival rate was low being detected in patients with a controlled primary tumor and distant resumption of the disease (14 patients / 62 patients in oncological evidence-22.58%).Median survival in patients with irradiated brain metastases was 7 months. Multivariate statistical analysis of the survival rate has detected statistically significant differences depending on the type of the primary tumor (p = 0.000) and the manner of the onset of brain metastases as the first manifestation or evolution of neoplastic disease (p = 0.000).Survival was affected, without statistical significance threshold, by the number of metastases, patient gender and the loco-regional status of the primary tumor.
    Keywords: Brain metastases, treatment, latency-free interval, survival rate

DOI 10.12865/CHSJ.42.04.07 


All articles in this issue

Volume 42 Issue 4 2016